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Abstract
Antimicrobial effector mechanisms are central to the function of the innate immune response in host defense against
microbial pathogens. In humans, activation of Toll-like receptor 2/1 (TLR2/1) on monocytes induces a vitamin D dependent
antimicrobial activity against intracellular mycobacteria. Here, we report that TLR activation of monocytes triggers induction
of the defensin beta 4 gene (DEFB4), requiring convergence of the IL-1b and vitamin D receptor (VDR) pathways. TLR2/1
activation triggered IL-1b activity, involving the upregulation of both IL-1b and IL-1 receptor, and downregulation of the IL-1
receptor antagonist. TLR2/1L induction of IL-1b was required for upregulation of DEFB4, but not cathelicidin, whereas VDR
activation was required for expression of both antimicrobial genes. The differential requirements for induction of DEFB4 and
cathelicidin were reflected by differences in their respective promoter regions; the DEFB4 promoter had one vitamin D
response element (VDRE) and two NF-kB sites, whereas the cathelicidin promoter had three VDREs and no NF-kB sites.
Transfection of NF-kB into primary monocytes synergized with 1,25D3 in the induction of DEFB4 expression. Knockdown of
either DEFB4 or cathelicidin in primary monocytes resulted in the loss of TLR2/1-mediated antimicrobial activity against
intracellular mycobacteria. Therefore, these data identify a novel mechanism of host defense requiring the induction of IL-1b
in synergy with vitamin D activation, for the TLR-induced antimicrobial pathway against an intracellular pathogen.
Citation: Liu PT, Schenk M, Walker VP, Dempsey PW, Kanchanapoomi M, et al. (2009) Convergence of IL-1b and VDR Activation Pathways in Human TLR2/1-
Induced Antimicrobial Responses. PLoS ONE 4(6): e5810. doi:10.1371/journal.pone.0005810
Editor: Derya Unutmaz, New York University School of Medicine, United States of America
Received March 9, 2009; Accepted May 5, 2009; Published June 5, 2009
Copyright:  2009 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Grant support for this work: Robert L. Modlin (NIH RO1 AI047868), Valencia P. Walker (NIH K12 HD034610 and Robert Wood Johnson Foundation
053510)and Mirjam Schenk (Swiss National Foundation 117533). The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: philip@bruinphd.com
Introduction
The innate immune system rapidly responds to infectious
pathogens, through recognition of microbial ligands and subsequent
triggering of an antimicrobial response. For the intracellular pathogen
Mycobacterium tuberculosis, a key antimicrobial mechanism involves
recognition of bacterial lipoproteins by Toll-like receptors (TLRs),
induction of the 25-hydroxyvitamin D3-1a-hydroxylase (CYP27B1),
which converts the vitamin D prohormone (25D) into the active
1,25D form, upregulation and activation of the vitamin D receptor
(VDR) [1–5]. Single nucleotide polymorphisms in the VDR confer
increased susceptibility to tuberculosis, suggested a key role for VDR
activation in host defense against tuberculosis in humans [6].
It has long been known that activation of the VDR alone in
human monocytes induces an antimicrobial activity against M.
tuberculosis, first demonstrated in the laboratories of Crowle and
Rook by addition of the VDR agonist [7,8]. We reasoned that the
VDR-induced antimicrobial pathway involves a set of regulated
genes that contribute to host defense against M. tuberculosis
infection. Vitamin D receptor response elements (VDREs) have
been shown to regulate the antimicrobial peptides cathelicidin and
defensin beta 4 (DEFB4, formerly HBD2) [1]. Previously, we
demonstrated that cathelicidin directly kills M. tuberculosis [3], and
furthermore, vitamin D-induced expression of cathelicidin was
required for antimicrobial activity [4]. In contrast, VDR activation
alone was not sufficient to induce DEFB4 expression in monocytes
[4]. Here we investigated the mechanism by which activation of
the innate system could induce DEFB4 expression in human
monocytes.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the University of California at Los
Angeles. All donors provided written informed consent for the
collection of peripheral blood and subsequent analysis.
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Reagents and bacteria
TLR2/1L is a synthetic 19 kDa M. tuberculosis derived
lipopeptide (EMC Microcollections, Tuebingen, Germany). Op-
timal induction of cathelicidin by TLR2/1L was performed at
24 hours based on previous time course experiments (data not
shown). 1,25D3 was purchased (BioMol, Plymouth Meeting, PA,
USA) and resuspended in sterile filtered ethanol at 1022 M in
amber tubes and stored at 280uC in small aliquots. 1,25D3 was
added to culture at a concentration of 1027 M to 1029 M, or
1028 M in the absence of a titration, the concentration previously
determined to be optimal for provocation of primary human
monocytes. VDR antagonist ZK 159 222 (VAZ) was provided
from Bayer Schering Pharma AG, and used at 1027 M to
1029 M, or 1028 M in the absence of a titration. M. tuberculosis
H37Ra strain was a kind gift from Dr. J. Ernst and utilized as
described below. Cathelicidin (Phoenix Pharmaceuticals, Burlin-
game, CA) and DEFB4 (Peptides International, Louisville, KY)
peptides were purchased and stored as recommended by the
manufacturer. The nonspecific peptide control is the 1–40 amino
acids of the amyloid-b protein (Peptides International), selected for
its similarity in both length and molecular weight to cathelicidin
and DEFB4 peptides, and it has no known antimicrobial activity.
Predesigned siRNA oligos were purchased (Dharmacon, Lafayette,
CO): siCTRL, siCath, and siDEFB4 were resuspended and stored
as recommended by the manufacturer. Cell Line Nucleofection
Kit V was purchased and used for siRNA transfections (Amaxa,
Gaithersburg, MD). IL-1b neutralizing antibody and recombinant
IL-1b were purchased and used at 10 mg/ml and 10 ng/ml
respectively (R&D Systems, Minneapolis, MN). NF-kB p65
expression vector was previously described [9].
Monocyte Isolation and Serum collection
Monocytes were isolated using Ficoll-Paque followed by Percoll
gradients (Amersham Biosciences, Piscataway, NJ) and cultured
with RPMI containing 10% of vitamin D-sufficient human sera,
and stimulated with the indicated conditions. For serum
collections, blood was drawn with no anticoagulants, and allowed
to clot for one hour. Then the clot was disrupted and centrifuged
to separate the serum, which was isolated and filtered. Both 25D
and 1,25D levels were measured as previously described [4]. Sera
from multiple vitamin D sufficient or borderline insufficient donors
were pooled and the bulk sera were supplemented with exogenous
25D3 to achieve 100 nM concentration if needed.
ELISA and Flow Cytometry
ELISAs were performed as previously described [10]. The IL-
1b antibody pair was purchased (Invitrogen, Carlsbad, CA). For
measuring IL-1RA levels, we utilized the Human IL-1RA Duoset
ELISA kit as recommended by the manufacturer (R&D System).
Detection of cell surface IL-1R1 levels was achieved using a three-
step flow cytometry assay. Briefly, following TLR2/1L stimula-
tion, cells were harvested from the culture plate and incubated
with the primary monoclonal antibody against IL-1R1 (R&D
Systems), then a biotinylated secondary antibody, and finally strep-
avidin conjugated with a fluorochrome. The three step flow
cytometry is necessary for the amplification of the fluorescent
signal due to the low expression levels of the IL-1R1 on human
primary monocytes.
Direct antimicrobial activity assay
Our previous studies demonstrate that the attenuated H37Ra
strain of M. tuberculosis has a similar susceptibility to cathelicidin
compared to the virulent H37Rv strain; therefore, we felt that
H37Ra is a sufficient model for the effects of antimicrobial
peptides on bacterial growth [3,4]. The direct antimicrobial
experiments were performed in conditions that are optimized for
cathelicidin activity and M. tuberculosis H37Ra grown as previously
described [4]. Briefly 26106 bacteria are incubated with
cathelicidin, DEFB4 or a non-specific peptide for two days, and
then pulsed with 3 mCi 3H-uracil for one day. Following
incubation, the bacteria were fixed at a final concentration of
2% paraformaldehyde for 20 minutes then harvested for liquid
scintillation counting. Antimicrobial activity was calculated as the
percent decrease in CPM values following treatment with the
peptide as compared to the no peptide control.
CFU Assay
Primary human monocytes were infected with M. tuberculosis
H37Ra at an MOI of 0.5 for 16 hours. The efficiency of infection
was determined by auramine rhodamine stain and was regularly in
the range of 30%, with an average of 1.1 bacteria per infected cell.
Infected cells were washed with 16PBS to remove extracellular
bacteria, counted, and plated into 96 well culture plates. The
infected cells were treated with TLR2/1L for three days in
triplicate wells, then lysed by resuspension into a 0.3% solution of
saponin with vigorous pipetting. Intracellular bacteria were
harvested for CFU assay as described [4]. To normalize for the
variable starting material per experiment, the relative CFU were
calculated by extrapolating the relative values of the TLR2/1L-
treated cells to 105 CFU of the media treated cells [3].
qPCR
RNA was isolated using Trizol Reagent (Invitrogen), and cDNA
was synthesized using the iSCRIPT cDNA Synthesis Kit (BioRad,
Hercules, CA). The primer sequences for 36B4, DEFB4 and
cathelicidin were previously published and methods described
[4,11]. The relative quantities of the gene tested per sample were
calculated against the ribosomal protein, large, P0 mRNA (36B4)
using the DDC(T) formula as previously described [12].
Primary monocyte transfection
Transfection of either siRNA or expression constructs into
primary human monocytes was accomplished using the AmaxaTM
Nucleofection System and the Human Monocyte Kit according to
the manufacturer’s recommendations. siRNA constructs were used
at 100 pmol per transfection, and plasmids at 1 mg per
transfection. Transfection efficiency of siRNA into primary
monocytes was assessed using siGLO, a fluorescently labeled
control oligo (Dharmacon) and averaged 95% transfection rate.
Transfection efficiency of expression constructs was assessed using
the pMAX-GFP construct (Amaxa), and yielded an average of
38% transfection rate.
Results
TLR2/1-activation results in upregulation of DEFB4 mRNA
As previously reported, direct activation of the VDR in primary
monocytes with 1,25D3 (1028 M) did not induce DEFB4 mRNA,
but was sufficient to induce a 25 fold increase in cathelicidin
expression (Student’s t-test, p,0.05) (Figure 1a) [4]. Similarly,
DEFB4 was not induced by monocytes activated with either
1027 M or 1029 M concentrations of 1,25D3 (data not shown).
The induction of cathelicidin by 1,25D3 in human monocytes, and
as previously shown the downstream target CYP24A1 suggested
that the VDR is functional [4], yet its activation is not sufficient to
induce DEFB4.
IL-1 and VDR in TLR2 Response
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To determine if other pathways were involved in the induction
of DEFB4 in monocytes, we considered TLR2/1 activation, a
powerful inducer of innate immune responses in monocytes,
including activation of the VDR as well as other signaling
pathways. In contrast to 1,25D3 stimulation, activation by the
TLR2/1 ligand (TLR2/1L, M. tuberculosis derived 19 kDa
lipopeptide) resulted in upregulation of DEFB4 mRNA by 4.2
fold (t-test, p,0.005). Cathelicidin was upregulated by 2.6 fold (t-
test, p,0.05) in the same experiments (Figure 1b), consistent with
previous results [4]. The TLR2/1L-induced DEFB4 mRNA
expression levels ranged from two to ten fold over media control,
with induction in some donors reaching levels of 30 to 70 fold over
media control (data not shown). These data indicate that DEFB4
induction can be triggered in human monocytes through
activation of TLR2/1.
TLR2/1-induced DEFB4 mRNA is dependent on activation
of the VDR
The ability of TLR2/1L but not 1,25D3 to activate DEFB4 in
human monocytes raised the question as to whether VDR
activation was required for DEFB4 induction. In order to address
this, the VDR antagonist ZK 159 222 (VAZ) was first tested for its
ability to block 1,25D3-induced cathelicidin mRNA expression.
Preincubation of monocytes with a titration of VAZ (1029 M to
1027 M) reduced 1,25D3-induced (1028 M) cathelicidin mRNA
in a dose dependent manner, resulting in a 56% reduction (t-test,
p,0.05) at equimolar concentrations and 87% reduction (t-test,
p,0.05) at 10-fold molar excess (Figure 2a). Monocytes were then
pretreated with VAZ (1028 M) followed by the TLR2/1L for
24 hours. mRNA levels of DEFB4 and cathelicidin were assessed
using qPCR. In the presence of VAZ, the TLR2/1L-mediated
Figure 1. Induction of antimicrobial peptides DEFB4 and cathelicidin from monocytes. (A) Primary human monocytes were stimulated
with 1,25D3 at 1028 M for 18 hours. Levels of DEFB4 or cathelicidin mRNA were determined using qPCR. (mean fold change vs media6SEM, n$5). (B)
Monocytes were stimulated with the TLR2/1L (10 mg/ml) for 24 hours. Levels of DEFB4 or cathelicidin mRNA were determined using qPCR. (mean fold
change vs media6SEM, n$4). NS = not significant, * = p#0.05, ** = p#0.01.
doi:10.1371/journal.pone.0005810.g001
IL-1 and VDR in TLR2 Response
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DEFB4 was reduced by 98% (t-test, p,0.001) and cathelicidin
mRNA expression was completely inhibited to levels below
unstimulated background calculated as a 120% reduction (t-test,
p,0.01) (Figure 2b). Taken together, these data demonstrate that
TLR2/1L-mediated induction of DEFB4 mRNA is dependent on
activation of the VDR.
IL-1b is required for TLR2/1L-mediated induction of
DEFB4 mRNA
The findings that TLR2/1-mediated induction of DEFB4 is VDR-
dependent, but 1,25D3 alone was not a sufficient trigger, suggested
that in addition, TLR2/1 activation induces a VDR-independent
immune mechanism. We hypothesized that IL-1b mediated the
Figure 2. Role of vitamin D receptor activation on the TLR2/1-induced DEFB4 expression. (A) Monocytes were treated with vitamin D
receptor antagonist ZK 159 222 (VAZ) at 1027 M, 1028 M, 1029 M or media for 20 minutes then activated with 1,25D3 at 1028 M for 18 hours. Levels
cathelicidin mRNA were determined using qPCR. (mean fold change vs media6SEM, n = 4). (B) Monocytes were treated with VAZ 1028 M or media for
20 minutes then activated with the TLR2/1L (10 mg/ml) for 24 hours. Levels of DEFB4 or cathelicidin mRNA were determined using qPCR (mean fold
change vs media6SEM, n$4). * = p#0.05, ** = p#0.01.
doi:10.1371/journal.pone.0005810.g002
IL-1 and VDR in TLR2 Response
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TLR2/1-induced DEFB4 expression given that: i) IL-1b was able to
trigger DEFB4 expression in epithelial cells [1] and ii) TLR activation
of monocytes resulted in the secretion of IL-1b [13,14]. To determine
whether TLR2/1-dependent induction of DEFB4 in primary human
monocytes required production of IL-1b, monocytes were pretreated
with IL-1b neutralizing monoclonal antibody, or IgG isotype control
for 20 minutes then cultured in human serum and stimulated with
TLR2/1L. The presence of the IL-1b neutralizing antibody resulted
in 97% reduction in the TLR2/1L-induced DEFB4 mRNA
expression (t-test, p,0.05), but had no effect on cathelicidin
expression (Figure 3a). These data suggest that induction of IL-1b
is required for TLR2/1-mediated induction of DEFB4 but not
cathelicidin.
Given these results, we tested if co-stimulation of monocytes
with IL-1b and 1,25D3 could induce DEFB4 expression.
Monocytes stimulated with either media, recombinant human
IL-1b (10 ng/ml), 1,25D3 (1028 M), or IL-1b and 1,25D3
together for 24 hours and assayed for DEFB4 and cathelicidin
mRNA expression. IL-1b alone did not induce expression of either
DEFB4 or cathelicidin mRNA, and 1,25D3 alone induced a 50-
fold increase in cathelicidin mRNA expression (t-test, p,0.01)
(Figure 3b). However, when added together, IL-1b and 1,25D3
did not induce DEFB4 mRNA, despite a 40-fold upregulation of
cathelicidin mRNA (t-test, p,0.01) (Figure 3b). These results
indicate that TLR2/1-induced DEFB4 mRNA expression requires
the release of both IL-1b and activation of the VDR, but the
addition of IL-1b and the VDR agonist together are not sufficient
to induce DEFB4 mRNA expression.
TLR2/1L triggers IL-1b, IL-1R1 and inhibits IL-1RA from
monocytes
We hypothesized that TLR2/1 activation on monocytes leads to
potentiation of IL-1b function based upon the following observa-
tions, 1) both IL-1b and activation of the VDR are required for
TLR2/1-mediated induction of DEFB4, and 2) co-stimulation with
IL-1b and 1,25D3 did not induce DEFB4. Therefore, three key
factors that can influence IL-1b activity were assayed in TLR2/1
stimulated monocytes: IL-1b6IL-1 receptor antagonist (IL-1RA)
and IL-1 receptor 1 (IL-1R1). Primary human monocytes were
isolated and treated with a titration of TLR2/1L (0.1 mg/ml, 1 mg/
ml, and 10 mg/ml) for 18 hours, then IL-1b and IL-1RA levels in
the culture supernatants were measured using ELISA. TLR2/1
stimulation resulted in significant IL-1b secretion in a dose
dependent manner reaching 2.8 ng/ml at the highest TLR2/1L
concentration tested (t-test vs media, p,0.05) (Figure 4a). Although
monocytes cultured in media alone exhibited spontaneous produc-
tion of IL-1RA, the addition of TLR2/1L reduced the release of IL-
1RA in a dose dependent manner (Figure 4b). At the highest
concentration of TLR2/1L (10 ug/ml) IL-1RA was reduced by
60% as compared to media (t-test, p,0.01). Next, cell surface
expression of IL-1R1 on monocytes stimulated with either media or
TLR2/1L (10 mg/ml) was measured by flow cytometry. TLR2/1
activation resulted in enhanced expression of IL-1R1 (Figure 4c)
equaling an average 3.1 fold increase in mean fluorescence intensity
(t-test, p,0.05) (Figure 4d). Taken together, these data demonstrate
that TLR2/1 stimulation of monocytes increases IL-1b activity
through the secretion of IL-1b, increased expression of IL-1R1 and
inhibition of IL-1RA.
We hypothesized that TLR2/1 stimulated monocytes would be
more sensitive to IL-1b stimulation due to the higher IL-1R1
expression and lower IL-1RA secretion. To test this, primary
monocytes cultured in human serum were treated with media,
recombinant IL-1b, TLR2/1L, or both simultaneously for
24 hours and assayed for DEFB4 and cathelicidin mRNA
expression. Consistent with the previous results, addition of
recombinant IL-1b to the culture medium alone did not induce
either DEFB4 or cathelicidin mRNA (Figure 4e), and again,
TLR2/1L induced expression of DEBF4 and cathelicidin
mRNAs. However, when monocytes were co-treated with both
IL-1b and TLR2/1L, DEFB4 mRNA expression levels were
synergistically increased by three fold over TLR2/1L alone (t-test,
p,0.01), but cathelicidin levels were unaffected (Figure 4e). In
addition, IL-1b did not increase the TLR2/1-induced expression
of either CYP27B1 or the VDR, both key genes in the vitamin D
pathway (Figure S1). These experiments demonstrate that TLR2/
1 stimulation sensitizes monocytes to IL-1b activation.
NF-kB activation drives expression of DEFB4 mRNA in
monocytes
In order to gain insight into the underlying mechanism for the
differential requirements for IL-1b activation of monocytes in the
induction of DEFB4 versus cathelicidin, their respective upstream
promoters regions were analyzed for regulatory elements by
MatInspector. Three vitamin D receptor response elements
(VDREs) were located in the cathelicidin promoter at positions
2144, 2502, and 2653 as compared to only one in the DEFB4
promoter at position 2938 (Figure 5a). Interestingly, there were
two NF-kB response elements found in the DEFB4 promoter at
positions 2406 and 2795, whereas none were present in the
cathelicidin promoter region (Figure 5a). Previously published
studies have verified all of the above mentioned response elements
to be bona fide promoter elements for their respective transcription
factors [1,15].
Based upon the presence of two NF-kB response elements in the
DEFB4 promoter, we determined whether NF-kB activation could
trigger monocytic expression of DEFB4 mRNA. IL-1b has been
shown to induce the activation and nuclear translocation of the p65
and p50 NF-kB subunits, but does not activate c-Rel, RelB or p52 in
epithelial cells [15,16]. Therefore, primary human monocytes were
transfected with a plasmid expressing the p65 NF-kB subunit under
control of the CMV-promoter, or a CMV-GFP control plasmid. In
the context of CMV-p65 transfection, 1,25D3 stimulation of
monocytes resulted in a significant 4.6 fold increase in DEFB4
mRNA expression (t-test, p,0.05, n= 6), whereas in the CMV-
GFP control transfected cells, 1,25D3 did not induce DEFB4
expression (Figure 5b). CMV-p65 also induced a trend for
increasing DEFB4 expression (t-test, p = 0.14, n= 6) in the absence
of additional 1,25D3 (Figure 5b). On the other hand, transfection of
CMV-p65 trended towards inhibition of the 1,25D3 induced
cathelicidin expression by 77% (t-test, p = 0.08, n= 6) as compared
to the 1,25D3 elicited cathelicidin expression in the CMV-GFP
control transfected cells (Figure 5b). These data suggest that in
human monocytes, activation of both NF-kB and VDR response
elements are required for optimal induction of DEBF4.
DEFB4 peptide exhibits direct antimicrobial activity
Although human DEFB4 has been demonstrated to be
associated with M. tuberculosis in alveolar macrophages during
infection [17], the antimicrobial activity of DEFB4 against the
bacterium has not been studied. To address this, M. tuberculosis
(attenuated H37Ra strain) were incubated with DEFB4 peptide, or
cathelicidin peptide (LL-37), as well as an unrelated control
peptide (CTRL), at a range from 0.01 mg/ml to 10 mg/ml for
three days. Bacterial viability was then assessed using 3H-uracil
uptake assay. Cathelicidin peptide demonstrated a dose dependent
antimicrobial activity, corroborating previous results [2,4]. The
DEFB4 peptide demonstrated similar dose dependent antimicro-
bial capacity to cathelicidin. In contrast, the control peptide was
IL-1 and VDR in TLR2 Response
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unable to reduce bacterial viability (Figure 6a). The observed
antimicrobial activity for DEFB4 and cathelicidin at 10 mg/ml
compared to the control peptide was calculated as 44% (t-test,
p,0.001) and 41% (t-test, p,0.001), respectively (Figure 6b).
These results demonstrate that DEFB4 is directly antimicrobial
against M. tuberculosis.
Both DEFB4 and cathelicidin are required for TLR2/1-
mediated antimicrobial activity
We have previously demonstrated that induction of cathelicidin
was required for 1,25D3-mediated antimicrobial activity [3]. To
compare the role of DEFB4 and cathelicidin in the TLR2/1-
mediated antimicrobial pathway, siRNA technology was used to
Figure 3. Role of IL-1b activation on DEFB4 expression. (A) Monocytes were incubated with the IL-1b neutralizing antibody (10 mg/ml), isotype
control (10 mg/ml) or media for 20 minutes, and then activated with TLR2/1L (10 mg/ml) for 24 hours. Levels of DEFB4 or cathelicidin mRNA were
determined using qPCR (mean fold change vs media6SEM, n$4). (B) Monocytes were stimulated with either media, TLR2/1L (10 mg/ml), recombinant
IL-1b (10 ng/ml), or both for 24 hours. Levels of DEFB4 or cathelicidin mRNA were determined using qPCR (mean fold change vs media6SEM, n = 5).
NS = not significant, * = p#0.05, ** = p#0.01.
doi:10.1371/journal.pone.0005810.g003
IL-1 and VDR in TLR2 Response
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knock down specific gene expression. Primary human monocytes
were transfected with siRNA oligos complementary to the DEFB4
mRNA (siDEFB4), the cathelicidin mRNA (siCath), or a non-
specific control oligo (siCTRL). The transfected cells were treated
with the TLR2/1L for 24 hours, and then expression of
cathelicidin and DEFB4 mRNAs were measured. siDEFB4 and
siCath both completely knocked-down the TLR2/1L-induced
expression of their respective targets, whereas siCTRL had no
effect (Figure S2).
Subsequently, monocytes transfected with siDEFB4, siCath and
siCTRL as well as untransfected monocytes were infected with M.
tuberculosis H37Ra at an MOI of 0.5 for 18 hours. The infected
cells were then treated with media or TLR2/1L for three days,
and their intracellular bacterial viability was determined by colony
forming units assay (CFU). In one representative experiment,
treatment with TLR2/1L reduced the viability of the intracellular
bacteria in the untransfected and siCTRL transfected cells by 30%
and 36% respectively (Figure 7a). In contrast, transfection of
monocytes with siCath or siDEFB4 ablated the TLR2/1L-induced
antimicrobial activity (Figure 7a). TLR2/1L treatment of
untransfected and siCTRL transfected monocytes resulted in an
average antimicrobial activity of 20% (t-test vs media, p,0.001)
and 14% (t-test vs media, p,0.05), respectively (Figure 5b).
However, transfection with siCath or siDEFB4 resulted in a 134%
Figure 5. Role of NF-kB activation on TLR2/1-induced DEFB4. (A) Promoter analysis for 1 kb upstream region for cathelicidin and DEFB4,
representing NF-kB binding sites and vitamin D response elements (VDRE). Monocytes were transfected with either an NF-kB p65 expression
construct (CMV-p65) or a control plasmid, and then stimulated with 1,25D3 (1028 M) for 18 hours. (B) DEFB4 and (C) cathelicidin mRNA levels were
determined using qPCR (mean fold change vs media6SEM, n = 6). * = p#0.05.
doi:10.1371/journal.pone.0005810.g005
Figure 4. Regulation of IL-1b activity by TLR activation. Monocytes were stimulated with the TLR2/1L at 0.1 mg/ml, 1 mg/ml or 10 mg/ml for
18 hours. (A) IL-1b or (B) IL-1RA levels in culture supernatants were measured using ELISA (mean levels6SEM, n= 5). Monocytes were stimulated with
TLR2/1L (10 mg/ml) for 24 hours. Cell surface expression of IL-1R1was assayed using flow cytometry. Data shown are (C) representative of three
individual donors, or (D) the mean DMFI (n = 3). (E) Monocytes stimulated with either media, TLR2/1L (10 mg/ml), recombinant IL-1b (10 ng/ml) or
both for 24 hours. Levels of DEFB4 or cathelicidin mRNA were determined using qPCR (mean fold change vs media6SEM, n = 5). NS =not significant,
* = p#0.05, ** = p#0.01.
doi:10.1371/journal.pone.0005810.g004
IL-1 and VDR in TLR2 Response
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and 107% reduction of TLR2/1L-induced antimicrobial activity
as compared to siCTRL transfected cells, respectively (t-test,
p,0.05), indicating enhancement of bacterial growth (Figure 7b).
These data suggest that the TLR2/1L-induced expression of both
DEFB4 and cathelicidin are required for optimal antimicrobial
activity against intracellular mycobacterial infection in human
monocytes.
Discussion
The mechanisms by which TLR2/1 activation of monocytes
triggers a vitamin D-dependent induction of antimicrobial activity
are central to host defense against intracellular M. tuberculosis [4].
Here we demonstrate that convergence of IL-1b and vitamin D
transcriptional activation induced expression of the antimicrobial
peptide DEFB4. Importantly, TLR2/1L activation triggered IL-
1b activity, involving the upregulation of both IL-1b and IL-1
receptor, and downregulation of the IL-1 receptor antagonist
(Figure 8). TLR2/1L induction of IL-1b was required for
upregulation of DEFB4, but not cathelicidin, whereas VDR
activation was required for expression of both antimicrobial genes.
A synergy between NF-kB and VDR activation was sufficient to
upregulate expression of DEFB4. Finally, knockdown of either
DEFB4 or cathelicidin resulted in the loss of TLR2/1-induced
antimicrobial activity against intracellular mycobacteria. There-
fore, these data identify a novel mechanism of host defense
requiring the induction of two distinct signaling pathways,
involving IL-1bin synergy with vitamin D activation, for TLR-
induced antimicrobial activity against an intracellular pathogen.
Upon triggering TLR2/1 with lipopeptide, both human and
murine macrophages activate antimicrobial pathways against
intracellular mycobacteria [4,18]. In comparing the human and
mouse TLR-induced antimicrobial pathways, it is noteworthy that
the human antimicrobial response requires induction of multiple
antimicrobial peptides, both cathelicidin and DEFB4, as opposed to
the murine antimicrobial response which is dependent upon
generation of nitric oxide [18–20]. It remains to be determined if
the cathelicidin- and DEFB4-mediated antimicrobial activity is
bactericidal or bacteriostatic. In humans, both the cathelicidin and
DEFB4 promoters contain VDREs [1], VDR activation was
required for their induction, as well as TLR-induced antimicrobial
activity [4]. In contrast, there are no VDRE sites present in the
mouse cathelicidin promoter region [21], and to our knowledge
there are no other known vitamin D-dependent antimicrobial
peptides in the murine genome. Interestingly, 1,25D induces nitric
oxide generation in murine macrophages [22], although the role for
vitamin D in this murine TLR-induced antimicrobial response
remains to be determined. Although our data indicate that the
human innate immune system has evolved a powerful antimicrobial
mechanism against intracellular mycobacterial infection through
the vitamin D dependent production of antimicrobial peptides, it
does not preclude a role for nitric oxide [6,23,24] and other
mechanisms such as superoxide generation and autophagy [6,25].
Although VDR activation was required for induction of both
DEFB4 and cathelicidin, neutralization of IL-1b prior to TLR-
activation resulted in the loss of DEFB4 but not cathelicidin.
Analysis of the cathelicidin and DEFB4 promoter regions revealed
two NF-kB response elements present in the DEFB4 promoter
Figure 6. Direct antimicrobial activity of DEFB4 and cathelicidin peptides. M. tuberculosis H37Ra were incubated with a control peptide,
DEFB4 peptide or cathelicidin peptide at 0.01 mg/ml, 0.1 mg/ml, 1 mg/ml and 10 mg/ml as well as media for three days. Bacterial proliferation was
assayed using 3H-uracil up take. Data shown is (A) representative of three independent experiments, and (B) mean antimicrobial activity6SEM (n$5).
* = p#0.05, ** = p#0.01, *** = p#0.001.
doi:10.1371/journal.pone.0005810.g006
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region, and none in the cathelicidin promoter. In contrast, both
genes contained vitamin D response elements, one in DEFB4
promoter and three in cathelicidin. These data suggested a
potential mechanism by which IL-1b could uniquely influence the
TLR-induced expression of DEFB4 and not cathelicidin while
both genes shared a requirement for vitamin D. Transfection of
NF-kB p65, the predominant IL-1b induced NF-kB subunit
[15,16], into monocytes resulted in a significant expression of
DEFB4 only with VDR activation. In contrast, NF-kB p65
transfection decreased 1,25D3 induced cathelicidin, further
highlighting the differential regulation of these two antimicrobial
genes. However, the mechanism by which NF-kB p65 transfection
inhibits cathelicidin is currently unclear and warrants further
exploration. Taken together these data demonstrate a novel role
for IL-1b in the antimicrobial activity against intracellular
pathogens, through the induction of DEFB4 in synergy with
vitamin D. Furthermore, this suggests that there are two distinct
vitamin D-dependent TLR-induced antimicrobial mechanisms,
with DEFB4 expression also dependent on induction of IL-1b.
In addition to induction of IL-1b expression and VDR
activation, triggering of TLR2/1 was found to modulate IL-1b
activity by increasing the cell’s responsiveness to the secreted IL-
1b. The monocyte response to IL-1b was upregulated by TLR2/1
activation through the simultaneous secretion of IL-1b, upregula-
tion of cell surface IL-1R1 and downregulation of baseline IL-
1RA. Addition of IL-1b to TLR2/1L stimulated monocytes
resulted in synergistic upregulation of DEFB4, which reflects the
increased IL-1b responsiveness. On the other hand, IL-1b plus
1,25D3 did not induce expression of DEFB4, presumably because
the IL-1R1 was not upregulated and/or the IL-1RA was not
downregulated. These findings provide a potential molecular
mechanism for the previously known association of a high IL-1b/
low IL-1RA producing haplotype with pleural tuberculosis, a form
of the disease that generally resolves without chemotherapy [26].
In addition, there is also an elevated level of 1,25D in the pleural
effusion fluid compared to serum of the same individual, resulting
in an optimal local microenvironment for the induction of
antimicrobial responses, including cathelicidin and DEFB4 [27].
Furthermore, IL-1R1 has been demonstrated to be required for
host defense against M. tuberculosis in a murine model [28]. Given
that excessive activation of IL-1b results in tissue injury and sepsis
[29], IL-1b activity is subject to negative feedback by the IL-1RA
[30]. While both IL-1b and IL-1RA are produced during
inflammatory conditions, IL-1RA is also induced by anti-
inflammatory signals [29,31–36]. As such, the balance between
IL-1b and IL-1RA during an innate immune response plays a
major role the pathogenesis of inflammatory diseases such as
diabetes, arthritis, inflammatory bowel disease [37], and as
presented here, TLR-mediated host defense mechanisms.
Although TLR activation induces DEFB4 in both monocytes
and epithelial cells [4,38,39], IL-1b alone was not sufficient to
induce expression of DEFB4 in monocytes, yet it is a potent
inducer of DEFB4 in epithelial cells [40–42]. The differential
regulation of antimicrobial peptide expression in monocytes vs.
epithelial cells reflects the location of these cell types and the
immunomodulatory properties of antimicrobial peptides. Epithe-
Figure 7. Role of DEFB4 and cathelicidin in TLR-mediated antimicrobial activity. Monocytes were transfected with either siRNA oligos
specific for DEFB4 (siDEFB4) or cathelicidin (siCath) as well as a non-specific siRNA oligo (siCTRL) or no siRNA. The cells were then infected with M.
tuberculosis H37Ra at an MOI of 0.5 for 18 hours followed by treatment with the TLR2/1L for three days. Intracellular bacterial load was measured
using CFU assay. Data shown are (A) representative of six individual experiments, and (B) mean antimicrobial activity6SEM (n$6). * = p#0.05,
*** = p#0.001.
doi:10.1371/journal.pone.0005810.g007
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lial cells form the barrier at which pathogens are initially
encountered, and they efficiently utilize the antimicrobial peptide
family of genes, for host defense at body surfaces interacting with
the outside environment [38,43–45]. However, in addition to their
antimicrobial activity, b-defensins and cathelicidin trigger inflam-
mation, by their chemotactic activity for innate and adaptive
immune cells such as monocytes, neutrophils, mast cells, dendritic
cells and T cells [46]. At body surfaces the antimicrobial peptides
are rapidly shed, such that this inflammatory activity is transient,
but when released in tissues, the resulting inflammatory cell
infiltrate contributes to immune-mediated injury, a complication
of host defense in chronic infectious diseases including mycobac-
terial infections such as leprosy, tuberculosis and Buruli ulcer.
Therefore, the more stringent regulation for monocytic expression
of cathelicidin and DEFB4 could potentially represent a
mechanism to prevent tissue injury in confined spaces.
IL-1b is clearly pivotal to host defense against microbial
pathogens, required for cell recruitment and induction of
inflammation, but also augmenting acquired lymphocyte responses
[29,47]. In murine models, a key role for IL-1 has been shown in
Figure 8. Model. Human TLR2/1L-mediated antimicrobial activity in monocytes requires two distinct pathways. Triggering TLR2/1L results in
activation of the vitamin D pathway, including expression of the VDR and CYP27B1, leading to induction of cathelicidin. On the other hand, TLR-
mediated expression of DEFB4 requires convergence of the IL-1b and VDR pathways. Activation of TLR2/1 results in regulation of IL-1b activity,
through the release of IL-1b expression of its receptor, IL-1R1, and simultaneous downregulation of the IL-1RA. Both cathelicidin and DEFB4 are
required for TLR2/1-mediated antimicrobial activity.
doi:10.1371/journal.pone.0005810.g008
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immunity to a variety of pathogens, including Listeria monocytogenes,
Staphylococcus aureus, and Helicobacter pylori [47–51]. Here, we have
identified a novel mechanism by which IL-1b contributes to
human host defense, requiring convergence of the TLR-induced
IL-1b and VDR pathways, to trigger expression DEFB4.
Furthermore, the data establish that the antimicrobial peptides,
DEFB4 and cathelicidin, are required effector molecules in the
TLR-induced antimicrobial response against intracellular myco-
bacteria in macrophages. Elucidation of the immune defense
mechanisms utilized by human macrophages to combat pathogens
provides possible targets for the development of new therapeutic
strategies, potentially useful given the emergence of multidrug
resistant strains of M. tuberculosis and other lethal microbes.
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